Vanguard Group Inc. increased its position in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 23.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,038,414 shares of the company’s stock after acquiring an additional 1,144,788 shares during the period. Vanguard Group Inc. owned about 0.07% of Immunome worth $129,705,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after purchasing an additional 14,398 shares during the period. Creative Planning acquired a new stake in Immunome in the 2nd quarter worth about $167,000. Rhumbline Advisers grew its holdings in Immunome by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after buying an additional 19,526 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Immunome by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after acquiring an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Immunome during the 2nd quarter valued at about $1,021,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. HC Wainwright initiated coverage on shares of Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price on the stock. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Truist Financial upgraded Immunome to a “strong-buy” rating in a report on Monday, May 4th. Finally, Craig Hallum lifted their price objective on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.45.
Insider Buying and Selling
In other news, CFO Max Rosett sold 65,000 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the completion of the transaction, the chief financial officer directly owned 54,037 shares in the company, valued at approximately $1,184,491.04. This represents a 54.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the sale, the director directly owned 369,347 shares of the company’s stock, valued at $7,560,533.09. The trade was a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 139,438 shares of company stock worth $2,964,664. 7.21% of the stock is currently owned by corporate insiders.
Immunome Stock Up 2.5%
NASDAQ IMNM opened at $23.00 on Tuesday. Immunome, Inc. has a fifty-two week low of $7.42 and a fifty-two week high of $27.65. The business has a 50 day moving average price of $21.97 and a two-hundred day moving average price of $21.05. The stock has a market cap of $2.60 billion, a PE ratio of -9.50 and a beta of 2.11.
Immunome (NASDAQ:IMNM – Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Sell-side analysts anticipate that Immunome, Inc. will post -2.5 EPS for the current fiscal year.
Immunome Profile
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Featured Stories
- Five stocks we like better than Immunome
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
